0001769177-20-000003.txt : 20201117 0001769177-20-000003.hdr.sgml : 20201117 20201117143322 ACCESSION NUMBER: 0001769177-20-000003 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20201117 DATE AS OF CHANGE: 20201117 EFFECTIVENESS DATE: 20201117 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GENEOS Therapeutics, Inc. CENTRAL INDEX KEY: 0001769177 IRS NUMBER: 813107759 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-380790 FILM NUMBER: 201320664 BUSINESS ADDRESS: STREET 1: 660 WEST GERMANTOWN PIKE STREET 2: SUITE LL110 CITY: PLYMOUTH MEETING STATE: PA ZIP: 19462 BUSINESS PHONE: 267-440-4232 MAIL ADDRESS: STREET 1: 660 WEST GERMANTOWN PIKE STREET 2: SUITE LL110 CITY: PLYMOUTH MEETING STATE: PA ZIP: 19462 D 1 primary_doc.xml X0708 D LIVE 0001769177 GENEOS Therapeutics, Inc. 660 WEST GERMANTOWN PIKE SUITE LL110 PLYMOUTH MEETING PA PENNSYLVANIA 19462 267-440-4232 DELAWARE Aeneos Therapeutics, Inc. None Corporation true 2016 Niranjan Y. Sardesai c/o GENEOS Therapeutics, Inc. 660 West Germantown Pike, Suite LL110 Plymouth Meeting PA PENNSYLVANIA 19462 Executive Officer Director James Eadie c/o GENEOS Therapeutics, Inc. 660 West Germantown Pike, Suite LL110 Plymouth Meeting PA PENNSYLVANIA 19462 Director J. Joseph Kim c/o GENEOS Therapeutics, Inc. 660 West Germantown Pike, Suite LL110 Plymouth Meeting PA PENNSYLVANIA 19462 Director Casey Cunningham c/o GENEOS Therapeutics, Inc. 660 West Germantown Pike, Suite LL110 Plymouth Meeting PA PENNSYLVANIA 19462 Director Samuel Broder c/o GENEOS Therapeutics, Inc. 660 West Germantown Pike, Suite LL110 Plymouth Meeting PA PENNSYLVANIA 19462 Director Sangwoo Lee c/o GENEOS Therapeutics, Inc. 660 West Germantown Pike, Suite LL110 Plymouth Meeting PA PENNSYLVANIA 19462 Director Biotechnology Decline to Disclose 06b false 2020-11-12 false true false 0 11999995 10399998 1599997 false 4 0 0 0 false GENEOS Therapeutics, Inc. /s/ Niranjan Y. Sardesai Niranjan Y. Sardesai President and Chief Executive Officer 2020-11-17